Pharma supplier and service provider ACG will spend $200 million for what will be the India-based company’s first empty-capsule production facility in the U.S.

When Europe considered banning titanium dioxide in medicines, the pharma world braced for upheaval. With its short-term future in medicines secured, what’s next?

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules